Literature DB >> 21461744

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study.

Michael Rainer1, A Wuschitz, C Jagsch, C Erb, J-J Chirikdjian, H A M Mucke.   

Abstract

Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21461744     DOI： 10.1007/s00702-011-0623-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  22 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.

Authors:  Steven Ferris; Ralf Ihl; Philippe Robert; Bengt Winblad; Gudrun Gatz; Frank Tennigkeit; Serge Gauthier
Journal:  Alzheimers Dement       Date:  2009-09       Impact factor: 21.566

3.  Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Authors:  B Reisberg; L Schneider; R Doody; R Anand; H Feldman; H Haraguchi; R Kumar; U Lucca; C A Mangone; E Mohr; J C Morris; S Rogers; T Sawada
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.

Authors:  R Doody; Y Wirth; F Schmitt; H J Möbius
Journal:  Dement Geriatr Cogn Disord       Date:  2004-07-14       Impact factor: 2.959

5.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.

Authors:  O L Lopez; J T Becker; A S Wahed; J Saxton; R A Sweet; D A Wolk; W Klunk; S T Dekosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

6.  Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.

Authors:  Patrizia Mecocci; Anna Bladström; Karina Stender
Journal:  Int J Geriatr Psychiatry       Date:  2009-05       Impact factor: 3.485

7.  Long-term course and effectiveness of combination therapy in Alzheimer disease.

Authors:  Alireza Atri; Lynn W Shaughnessy; Joseph J Locascio; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

8.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

9.  Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

Authors:  David Wilkinson; Henning Friis Andersen
Journal:  Dement Geriatr Cogn Disord       Date:  2007-07-04       Impact factor: 2.959

10.  A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

Authors:  Christopher H van Dyck; Pierre N Tariot; Barnett Meyers; E Malca Resnick
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Apr-Jun       Impact factor: 2.703
View more
  7 in total

Review 1.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

Review 2.  Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Authors:  Carole Parsons; Wei Yin Lim; Clement Loy; Bernadette McGuinness; Peter Passmore; Stephanie A Ward; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2021-02-03

Review 3.  Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.

Authors:  Katherine A Lyseng-Williamson; Kate McKeage
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

4.  Anti-dementia drugs and co-medication among patients with Alzheimer's disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem).

Authors:  Seyed-Mohammad Fereshtehnejad; Kristina Johnell; Maria Eriksdotter
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

5.  Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease.

Authors:  Dayu Sun; Junhua Chen; Xiaohang Bao; Yulong Cai; Jinghui Zhao; Jing Huang; Wei Huang; Xiaotang Fan; Haiwei Xu
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

6.  NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines.

Authors:  William G North; Fuli Liu; Ruiyang Tian; Hamza Abbasi; Bonnie Akerman
Journal:  Clin Pharmacol       Date:  2015-10-23

Review 7.  Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.

Authors:  Ivana Molino; Luisa Colucci; Angiola M Fasanaro; Enea Traini; Francesco Amenta
Journal:  ScientificWorldJournal       Date:  2013-10-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.